Robert Lutjens - Addex Therapeutics Head Biology
| ADXN Stock | CHF 0.06 0 6.01% |
Insider
Robert Lutjens is Head Biology of Addex Therapeutics
| Age | 55 |
| Phone | (41) 22 884 15 56 |
| Web | www.addexpharma.com |
Addex Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.8786) % which means that it has lost $0.8786 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.0267) %, meaning that it generated substantial loss on money invested by shareholders. Addex Therapeutics' management efficiency ratios could be used to measure how well Addex Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Carsten Daweritz | Evolva Holding SA | 50 | |
| Ravi Anand | Newron Pharmaceuticals SpA | 66 | |
| Eva Kalias | Santhera Pharmaceuticals Holdin | N/A | |
| Sarah HolmesKlotz | Santhera Pharmaceuticals Holdin | N/A | |
| Davide Malavasi | COSMO Pharmaceuticals SA | 50 | |
| Roberto Galli | Newron Pharmaceuticals SpA | N/A | |
| Giulio Evangelisti | COSMO Pharmaceuticals SA | 53 | |
| Shabir MD | Santhera Pharmaceuticals Holdin | N/A | |
| Adesh Kaul | Basilea Pharmaceutica AG | 49 | |
| Philipp Frech | Evolva Holding SA | N/A | |
| Fabienne Gschwind | Evolva Holding SA | 50 | |
| Hazel Winchester | COSMO Pharmaceuticals SA | 52 | |
| Ursula Eberhardt | Basilea Pharmaceutica AG | 61 | |
| Niall Donnelly | COSMO Pharmaceuticals SA | 51 | |
| David Veitch | Basilea Pharmaceutica AG | 58 | |
| Anne Vos | Evolva Holding SA | 59 | |
| Marco Lecchi | COSMO Pharmaceuticals SA | 59 | |
| FCMA CGMA | Santhera Pharmaceuticals Holdin | 60 | |
| Alessandro LLM | COSMO Pharmaceuticals SA | 60 | |
| Gnther Metz | Santhera Pharmaceuticals Holdin | 65 | |
| Astrid Schafer | Evolva Holding SA | 50 | |
Management Performance
| Return On Equity | -2.03 | |||
| Return On Asset | -0.88 |
Addex Therapeutics Leadership Team
Elected by the shareholders, the Addex Therapeutics' board of directors comprises two types of representatives: Addex Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Addex. The board's role is to monitor Addex Therapeutics' management team and ensure that shareholders' interests are well served. Addex Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Addex Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Dyer, CEO CoFounder | ||
| Werner Henrichi, Consultant | ||
| Mikhail Kalinichev, Head Science | ||
| JeanPhilippe Rocher, Head Chemistry | ||
| Roger MD, Chief Director | ||
| Lnaic Teyssdou, Head Fin | ||
| Robert Lutjens, Head Biology |
Addex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Addex Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.03 | |||
| Return On Asset | -0.88 | |||
| Operating Margin | (17.07) % | |||
| Current Valuation | 2.92 M | |||
| Shares Outstanding | 115.35 M | |||
| Shares Owned By Insiders | 8.96 % | |||
| Shares Owned By Institutions | 9.31 % | |||
| Price To Earning | 39.53 X | |||
| Price To Book | 1.62 X | |||
| Price To Sales | 9.82 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Addex Stock Analysis
When running Addex Therapeutics' price analysis, check to measure Addex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Addex Therapeutics is operating at the current time. Most of Addex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Addex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Addex Therapeutics' price. Additionally, you may evaluate how the addition of Addex Therapeutics to your portfolios can decrease your overall portfolio volatility.